NCT06635824: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Sponsor: Genmab. Phase: PHASE3. Conditions: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC